会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明授权
    • Water soluble azoles as broad-spectrum antifungals
    • 水溶性唑类作为广谱抗真菌剂
    • US06384030B1
    • 2002-05-07
    • US09700251
    • 2000-11-09
    • Lieven MeerpoelLeo Jacobus Jozef BackxLouis Jozef Elisabeth Van der VekenJan HeeresFrank Christopher Odds
    • Lieven MeerpoelLeo Jacobus Jozef BackxLouis Jozef Elisabeth Van der VekenJan HeeresFrank Christopher Odds
    • C07D40514
    • C07D249/08C07D231/12C07D233/56C07D249/12
    • The present invention concerns novel compounds of formula the N-oxide forms, the pharmaceutically acceptable addition salts and stereochemically isomeric forms thereof, wherein L represent a radical of formula wherein each Alk independently represents an optionally substituted C1-6alkanediyl; is 1, 2 or 3; Y is O, S or NR2; R1 represents hydrogen, aryl, Het1, or an optionally substituted C1-6alkyl; each R2 independently represents hydrogen or C1-6alkyl; or in case R1 and R2 are attached to the same nitrogen atom, they may be taken together to form a heterocyclic radical; or they may be taken together to form an azido radical; each R3 independently represents hydrogen, hydroxy or C1-4alkyloxy; aryl represents phenyl, naphthalenyl, 1,2,3,4-tetrahydro-naphthalenyl, indenyl or indanyl; each of said aryl groups may optionally be substituted; Het1 represents an optionally substituted monocyclic or bicyclic heterocyclic radical; Het2 is the same as Het1 and may also be piperazinyl, homopiperazinyl, 1,4-dioxanyl, morpholinyl, thiomorpholinyl; R6 represents hydrogen or C1-4alkyl; R7 represents hydrogen or C1-4alkyl; or R6 and R7 taken together form a bivalent radical of formula —N═CH— (i), —CH═N— (ii), —CH═CH— (iii), —CH2—CH2 (iv), wherein one hydrogen atom in the radicals (i) and (ii) may be replaced with a C1-4alkyl radical and one or more hydrogen atoms in radicals (iii) and (iv) may be replaced by a C1-4alkyl radical; D represents a trisubstituted 1,3-dioxolane derivative; as antifungals; their processes for preparation, compositions containing them and their use as a medicine.
    • 本发明涉及配制N-氧化物形式的新化合物,其药学上可接受的加成盐和立体化学异构形式,其中L代表甲酰基的基团,每个Alk独立地表示任选取代的C 1-6烷二基; 是1,2或3; Y是O,S或NR2; R 1表示氢,芳基,Het1或任选取代的C 1-6烷基; 每个R 2独立地表示氢或C 1-6烷基; 或者在R1和R2连接到相同的氮原子的情况下,它们可以一起形成杂环基; 或者它们可以一起形成叠氮基; 每个R 3独立地表示氢,羟基或C 1-4烷氧基; 芳基表示苯基,萘基,1,2,3,4-四氢 - 萘基,茚基或茚满基; 每个所述芳基可任选被取代; Het1表示任选取代的单环或双环杂环基; Het2与Het1相同,也可以是哌嗪基,高哌嗪基,1,4-二氧杂环己基,吗啉基,硫代吗啉基; R6代表氢或C1-4烷基; R7代表氢或C1-4烷基; 或者R 6和R 7一起形成式-N = CH-(ⅰ),-CH = N-(ⅱ),-CH = CH-(ⅲ),-CH 2 -CH 2(ⅳ)的二价基团,其中一个氢 基团(i)和(ii)中的原子可以被C 1-4烷基取代,并且基团(iii)和(iv)中的一个或多个氢原子可被C 1-4烷基取代; D表示三取代的1,3-二氧戊环衍生物; 作为抗真菌剂; 其制备方法,含有它们的组合物及其作为药物的用途。
    • 5. 发明授权
    • Adamantyl pyrrolidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
    • 金刚烷基吡咯烷-2-酮衍生物作为11-β羟基类固醇脱氢酶抑制剂
    • US07687644B2
    • 2010-03-30
    • US11632195
    • 2005-04-29
    • Libuse JaroskovaJoannes Theodorus Maria LindersChristophe Francis Robert BuyckLouis Jozef Elisabeth Van der Veken
    • Libuse JaroskovaJoannes Theodorus Maria LindersChristophe Francis Robert BuyckLouis Jozef Elisabeth Van der Veken
    • C07D207/00A61K31/40
    • C07D207/26C07D207/267C07D211/76C07D453/06
    • the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein n is 1 or 2; M represents a direct bond or a C1-3alkyl linker optionally substituted with one or two substituents selected from C1-4alkyl, C1-3alkyloxy-C1-4alkyl-, hydroxy-C1-4alkyl-, hydroxy, C1-3alkyloxy- or phenyl-C1-4alkyl-; R1 and R2 each independently represent hydrogen, halo, cyano, hydroxy, C1-4alkyl optionally substituted with halo, C1-4alkyloxy-optionally substituted with one or where possible two or three substituents selected from hydroxy, Ar1 and halo; R3 represents hydrogen, halo, C1-4alkyl, C1-4alkyloxy-, cyano or hydroxy; R4 represents hydrogen, halo, C1-4alkyl, hydroxy, cyano or C1-4alkyloxy-optionally substituted with one or where possible two or three substituents selected from hydroxy and halo; R5 represents hydrogen, C1-4alkyl or Ar2—C1-4alkyl-; R6 represents hydrogen, hydroxy, halo, C1-4alkyl or C1-4alkyoxy-; R7 represents hydrogen or R7 and R5 taken together with the carbon atom to which they are attached from a —C2-alkyl-linker; Ar1 and Ar2 each independently represent phenyl or naphtyl wherein said phenyl and naphtyl are optionally substituted with C1-4alkyl, C1-4alkyloxy-, or phenyl-C1-4alkyl.
    • N-氧化物形式,其药学上可接受的加成盐及其立体化学异构形式,其中n为1或2; M表示直接键或任选被一个或两个选自C 1-4烷基,C 1-3烷氧基-C 1-4 - 烷基 - ,羟基-C 1-4 - 烷基 - ,羟基,C 1-3烷氧基 - 或苯基-C 1 -4-烷基 - ; R 1和R 2各自独立地表示氢,卤素,氰基,羟基,任选被卤素取代的C 1-4烷基,C 1-4烷氧基 - 任选被一个或可能的两个或三个选自羟基,Ar 1和卤素的取代基取代; R 3表示氢,卤素,C 1-4烷基,C 1-4烷氧基 - ,氰基或羟基; R 4表示氢,卤素,C 1-4烷基,羟基,氰基或C 1-4烷氧基 - 任选地被一个或其中可能的两个或三个选自羟基和卤素的取代基取代; R5表示氢,C1-4烷基或Ar2-C1-4烷基 - ; R 6表示氢,羟基,卤代,C 1-4烷基或C 1-4烷氧基 - ; R 7代表氢或R 7和R 5与它们所连接的碳原子一起从-C2-烷基 - 连接基中取代; Ar 1和Ar 2各自独立地表示苯基或萘基,其中所述苯基和萘基任选被C 1-4烷基,C 1-4烷氧基或苯基-C 1-4烷基取代。